Perfluorooctanoic acid effects on ovaries mediate its inhibition of peripubertal mammary gland development in Balb/c and C57Bl/6 mice

Reproductive Toxicology

Volumn 33, Issue 4, 2012, Pages 563-576

  Zhao, Yong ^a   Tan, Ying S ^a   Strynar, Mark J ^b   Perez, Gloria ^a   Haslam, Sandra Z ^a   Yang, Chengfeng ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Growth factors; Mammary gland development; Perfluorooctanoic acid (PFOA); Peroxisome proliferator activated receptor (PPAR ); Puberty; Steroid hormones

Indexed keywords

17(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; AMPHIREGULIN; AROMATASE; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; GROWTH FACTOR; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 3; OXIDOREDUCTASE; PERFLUOROOCTANOIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PROGESTERONE; SCATTER FACTOR; SOMATOMEDIN; STEROIDOGENIC ACUTE REGULATORY PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; BODY WEIGHT; BREAST DEVELOPMENT; CONTROLLED STUDY; ESTRUS CYCLE; EXPOSURE; FEMALE; FEMALE GENITAL SYSTEM FUNCTION; GROWTH INHIBITION; HORMONE SYNTHESIS; KNOCKOUT MOUSE; MOUSE; NONHUMAN; OVARY INSUFFICIENCY; PERIPUBERTAL EXPOSURE; PROTEIN EXPRESSION; STRAIN DIFFERENCE; SUPPLEMENTATION; TOXICITY TESTING; VAGINA OPENING; WILD TYPE;

ANIMALS; BLOTTING, WESTERN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENTAL POLLUTANTS; ESTROGENS; FEMALE; FLUOROCARBONS; KIDNEY; MAMMARY GLANDS, ANIMAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; OCTANOIC ACIDS; ORGANIC ANION TRANSPORTERS; OVARY; PPAR ALPHA; PROGESTERONE; REAL-TIME POLYMERASE CHAIN REACTION; SEXUAL MATURATION; SPECIES SPECIFICITY; TISSUE DISTRIBUTION;

MUS;

EID: 84862780855     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2012.02.004     Document Type: Article

References (47)

1. Abbott B.D., Wolf C.J., Schmid J.E., Das K.P., Zehr R.D., Helfant L., et al. Perfluorooctanoic acid induced developmental toxicity in the mouse is dependent on expression of peroxisome proliferator activated receptor-alpha. Toxicol Sci 2007, 98(2):571-581.
2. Lau C., Anitole K., Hodes C., Lai D., Pfahles-Hutchens A., Seed J. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol Sci 2007, 99(2):366-394.
3. White S.S., Calafat A.M., Kuklenyik Z., Villanueva L., Zehr R.D., Helfant L., et al. Gestational PFOA exposure of mice is associated with altered mammary gland development in dams and female offspring. Toxicol Sci 2007, 96(1):33-144.
4. Innes K.E., Ducatman A.M., Luster M.I., Shankar A. Association of osteoarthritis with serum levels of the environmental contaminants perfluorooctanoate and perfluorooctane sulfonate in a large appalachian population. Am J Epidemiol 2011, 174(4):440-450.
5. Kudo N., Kawashima Y. Toxicity and toxicokinetics of perfluorooctanoic acid in humans and animals. J Toxicol Sci 2003, 28(2):49-57.
6. Kennedy G.L., Butenhoff J.L., Olsen G.W., O'Connor J.C., Seacat A.M., Perkins R.G., et al. The toxicology of perfluorooctanoate. Crit Rev Toxicol 2004, 34(4):351-384.
7. Lau C., Butenhoff J.L., Rogers J.M. The developmental toxicity of perfluoroalkyl acids and their derivatives. Toxicol Appl Pharmacol 2004, 198(2):231-241.
8. Lau C., Thibodeaux J.R., Hanson R.G., Narotsky M.G., Rogers J.M., Lindstrom A.B., et al. Effects of perfluorooctanoic acid exposure during pregnancy in the mouse. Toxicol Sci 2006, 90(2):510-518.
9. Wolf C.J., Fenton S.E., Schmid J.E., Calafat A.M., Kuklenyik Z., Bryant X.A., et al. Developmental toxicity of perfluorooctanoic acid in the CD-1 mouse after cross-foster and restricted gestational exposures. Toxicol Sci 2007, 95(2):462-473.
10. White S.S., Kato K., Jia L.T., Basden B.J., Calafat A.M., Hines E.P., et al. Effects of perfluorooctanoic acid on mouse mammary gland development and differentiation resulting from cross-foster and restricted gestational exposures. Reprod Toxicol 2009, 27(3-4):289-298.
11. White S.S., Fenton S.E., Hines E.P. Endocrine disrupting properties of perfluorooctanoic acid. J Steroid Biochem Mol Biol 2011, 127(1-2):16-26.
12. Yang C., Tan Y.S., Harkema J.R., Haslam S.Z. Differential effects of peripubertal exposure to perfluorooctanoic acid on mammary gland development in C57Bl/6 and Balb/c mouse strains. Reprod Toxicol 2009, 27(3-4):299-306.
13. Zhao Y., Tan Y.S., Haslam S.Z., Yang C. Perfluorooctanoic acid effects on steroid hormone and growth factor levels mediate stimulation of peripubertal mammary gland development in C57BL/6 mice. Toxicol Sci 2010, 115(1):214-224.
14. Macon M.B., Villanueva L.R., Tatum-Gibbs K., Zehr R.D., Strynar M.J., Stanko J.P., et al. Prenatal perfluorooctanoic acid exposure in CD-1 mice: low dose developmental effects and internal dosimetry. Toxicol Sci 2011, 122(1):134-145.
15. Vanden Heuvel J.P., Kuslikis B.I., Van Rafelghem M.J., Peterson R.E. Tissue distribution, metabolism, and elimination of perfluorooctanoic acid in male and female rats. J. Biochem Toxicol 1991, 6(2):83-92.
16. Fenton S.E. Endocrine-disrupting compounds and mammary gland development: early exposure and later life consequences. Endocrinology 2006, 147(Suppl. 6):S18-S24.
17. Selevan S.G., Kimmel C.A., Mendola P. Identifying critical windows of exposure for children's health. Environ Health Perspect 2000, 108(Suppl. 3):451-455.
18. Imagawa W., Pedchenko V.K., Helber J., Zhang H. Hormone/growth factor interactions mediating epithelial/stromal communication in mammary gland development and carcinogenesis. J Steroid Biochem Mol Biol 2002, 80(2):213-230.
19. Sternlicht M.D. Key stages in mammary gland development: the cues that regulate ductal branching morphogenesis. Breast Cancer Res 2006, 8(1):201-211.
20. Ciarloni L., Mallepell S., Brisken C. Amphiregulin is an essential mediator of estrogen receptor alpha function in mammary gland development. Proc Natl Acad Sci U S A 2007, 104(13):5455-5460.
21. Kleinberg D.L., Ruan W., I.G.F-I. GH, and sex steroid effects in normal mammary gland development. J Mammary Gland Biol Neoplasia 2008, 13(4):353-360.
22. Niranjan B., Buluwela L., Yant J., Perusinghe N., Atherton A., Phippard D., et al. HGF/SF: a potent cytokine for mammary growth, morphogenesis and development. Development 1995, 121(9):2897-2908.
23. Soriano J.V., Pepper M.S., Orci L., Montesano R. Roles of hepatocyte growth factor/scatter factor and transforming growth factor-beta1 in mammary gland ductal morphogenesis. J Mammary Gland Biol Neoplasia 1998, 3(2):133-150.
24. Accornero P., Miretti S., Starvaggi Cucuzza L., Martignani E., Baratta M. Epidermal growth factor and hepatocyte growth factor cooperate to enhance cell proliferation, scatter and invasion in murine mammary epithelial cells. J Mol Endocrinol 2010, 44(2):115-125.
25. Mandard S., Müller M., Kersten S. Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci 2004, 61(4):393-416.
26. Rizzo G., Fiorucci S. PPARs and other nuclear receptors in inflammation. Curr Opin Pharmacol 2006, 6(4):421-427.
27. Abbott B.D. Review of the expression of peroxisome proliferator-activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development. Reprod Toxicol 2009, 27(3-4):246-257.
28. Tai P., Wang J., Jin H., Song X., Yan J., Kang Y., et al. Induction of regulatory T cells by physiological level estrogen. J Cell Physiol 2008, 214(2):456-464.
29. Gibson C.L., Coomber B., Murphy S.P. Progesterone is neuroprotective following cerebral ischaemia in reproductively ageing female mice. Brain 2011, 134(Pt 7):2125-2133.
30. Reiner J.L., Nakayama S.F., Delinsky A.D., Stanko J.P., Fenton S.E., Lindstrom A.B., et al. Analysis of PFOA in dosed CD1 mice. Part 1. Methods development for the analysis of tissues and fluids from pregnant and lactating mice and their pups. Reprod Toxicol 2009, 27(3-4):360-364.
31. Kudo N., Katakura M., Sato Y., Kawashima Y. Sex hormone-regulated renal transport of perfluorooctanoic acid. Chem Biol Interact 2002, 139(3):301-316.
32. Bronson FH, Dagg CP, Snell GD. Reproduction. In: Green EL, editor. Biology of the laboratory mouse. http://www.informatics.jax.org/greenbook/.
33. Curtis S.W., Clark J., Myers P., Korach K.S. Disruption of estrogen signaling does not prevent progesterone action in the estrogen receptor alpha knockout mouse uterus. Proc Natl Acad Sci U S A 1999, 96(7):3646-3651.
34. Das S.K., Chakraborty I., Paria B.C., Wang X.N., Plowman G., Dey S.K. Amphiregulin is an implantation-specific and progesterone-regulated gene in the mouse uterus. Mol Endocrinol 1995, 9(6):691-705.
35. Graham J.D., Clarke C.L. Physiological action of progesterone in target tissues. Endocr Rev 1997, 18(4):502-519.
36. Hewitt S.C., Korach K.S. Progesterone action and responses in the alphaERKO mouse. Steroids 2000, 65(10-11):551-557.
37. Miller W.L. Steroidogenic acute regulatory protein (StAR), a novel mitochondrial cholesterol transporter. Biochim Biophys Acta 2007, 1771(6):663-676.
38. Seto-Young D., Avtanski D., Strizhevsky M., Parikh G., Patel P., Kaplun J., et al. Interactions among peroxisome proliferator activated receptor-gamma, insulin signaling pathways, and steroidogenic acute regulatory protein in human ovarian cells. J Clin Endocrinol Metab 2007, 92(6):2232-2239.
39. Payne A.H., Hales D.B. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 2004, 25(6):947-970.
40. Land C.E., Tokunaga M., Koyama K., Soda M., Preston D.L., Nishimori I., et al. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1990. Radiat Res 2003, 160(6):707-717.
41. Cohn B.A., Wolff M.S., Cirillo P.M., Sholtz R.I. DDT and breast cancer in young women: new data on the significance of age at exposure. Environ Health Perspect 2007, 115(10):1406-1414.
42. Andersen M.E., Clewell H.J., Tan Y.M., Butenhoff J.L., Olsen G.W. Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys - probing the determinants of long plasma half-lives. Toxicology 2006, 227(1-2):156-164.
43. Weaver Y.M., Ehresman D.J., Butenhoff J.L., Hagenbuch B. Roles of rat renal organic anion transporters in transporting perfluorinated carboxylates with different chain lengths. Toxicol Sci 2010, 113(2):305-314.
44. Andersen M.E., Butenhoff J.L., Chang S.C., Farrar D.G., Kennedy G.L., Lau C., et al. Perfluoroalkyl acids and related chemistries - toxicokinetics and modes of action. Toxicol Sci 2008, 102(1):3-14.
45. Bjork J.A., Butenhoff J.L., Wallace K.B. Multiplicity of nuclear receptor activation by PFOA and PFOS in primary human and rodent hepatocytes. Toxicology 2011, 288(1-3):8-17.
46. Haughom B., Spydevold O. The mechanism underlying the hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctane sulphonic acid (PFOSA) and clofibric acid. Biochim Biophys Acta 1992, 1128(1):65-72.
47. Olsen G.W., Burris J.M., Ehresman D.J., Froehlich J.W., Seacat A.M., Butenhoff J.L., et al. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect 2007, 115(9):1298-1305.